At a glance
ClinicalIndex Comparison RecordN/ACompleted· 989 enrolled
Drug / intervention
Doxazosin mesylate GITSdrug
Likely dose
Doxazosin mesylate GITS 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post Marketing Surveillance Study To Determine The Safety, Tolerability And Effectiveness Of Doxazosin Mesylate GITS Among Filipino Adult Males With Benign Prostatic Hyperplasia (BPH)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Oct 29, 2009·Updated Jan 28, 2021
In Brief
An observational study evaluating Doxazosin mesylate GITS for Prostatic Hyperplasia. Completed, enrolled 989 participants across 67 sites.
Detailed Summary
This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Hyperplasia
CountriesPhilippines
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedOct 2009
Primary CompletionJan 2011
TodayJul 2026
First PostedOct 29, 2009
Enrollment StartMay 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.7 years ago
Interventions
Doxazosin mesylate GITSdrug
Doxazosin mesylate GITS 4mg to 8mg once daily